Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
October 05 2023 - 8:00AM
Business Wire
Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a
global innovation activation company focused on the discovery,
development, and deployment of technologies that monitor and
modulate the immune system, announced today that it has appointed
Ernie Lee to serve as the Chief Executive Officer of the Company’s
wholly-owned subsidiary Pearsanta, Inc. (“Pearsanta”). Ernie’s
appointment is intended to accelerate the commercial launch of
Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business
(“B2B”) and direct-to-consumer (“DTC”) clinical diagnostic testing
services platform for retail pharmacies, physician practices,
employee benefit programs, and consumers.
“Naming Ernie as CEO of Pearsanta, is a crucial initial step in
our plan to scale the company and capitalize on global
opportunities. With Ernie at the helm, we believe that
Test2Treat.me has the potential to quickly fill a void in the
healthcare market for DTC point-of-care testing and treatment,”
says Amro Albanna, co-founder, chairman, and CEO of Aditxt.
Mr. Lee brings over two decades of experience in the development
and distribution of innovative products and services to healthcare
providers. Previously, Mr. Lee was the CEO and Chief Marketing
Officer of FirstVitals Health and Wellness Inc., where he received
the 2012 Health Care Innovation Award from the Centers for Medicare
& Medicaid Services for the implementation of early diabetes
remote patient monitoring and care management services for
Medicaid’s underserved beneficiaries using a proprietary remote
patient monitoring platform. Mr. Lee holds a patent for an
innovative electronic healthcare payment system connecting
insurance payers and healthcare providers.
“I am excited to lead a company focused on the power of health
by the numbers. Episodic care will never be the same again with the
advent of our Test2Treat.me platform,” says Lee. “With physician
shortages and limited access to immediate care, Test2Treat.me meets
patient demand for personalized medicine that makes a real
difference in how efficiently patients are tested and treated.
Additionally, with increasing out-of-pocket costs for healthcare
services, we believe consumers will seek best-in-class clinical
diagnostic laboratory and professional services as direct
purchasers of healthcare services. Lessons learned from the COVID
experience: consumers are expecting rapid turnaround time for lab
tests with the convenience of online consultations with healthcare
providers, and Test2Treat.me was designed to meet this new
demand.”
Visit Test2Treat.me and Pearsanta.com to stay up to date on
upcoming product developments. Visit Aditxt.com to learn more about
the life-changing health technology innovations the company
discovers, develops, and deploys that invoke global change around
immune health care.
About Aditxt, Inc.
Aditxt, Inc.® (NASDAQ: ADTX) is a global innovation company
focused on discovering, developing and deploying technologies that
monitor and modulate the immune system. Headquartered in Richmond,
Virginia, with operations in Mountain View, California, and
Melville, New York. Aditxt’s mission of “Making Promising
Innovations Possible, Together” is defined by our growing ecosystem
of research institutions, global industry partners, and
shareholders who inform and inspire our mission. Aditxt’s diverse
innovation portfolio includes: Adimune™, Inc., developing and
designing a new class of therapeutics for retraining the immune
system to address organ rejection, autoimmunity, and allergies;
Adivir™, Inc., focused on identifying, developing and
commercializing new ways to treat infectious diseases; and
Pearsanta™, Inc., offering convenient, rapid, personalized, and
high-quality lab testing —anytime and anywhere at their CLIA
certified and CAP accredited clinical laboratory based in Richmond,
VA. For more information, visit the Company’s websites at
www.Aditxt.com, www.Adimune.com, and
www.Pearsanta.com. Follow us on LinkedIn for the latest company
news.
About Pearsanta, Inc.
Formed in January 2023 as a wholly owned Aditxt subsidiary,
Pearsanta, Inc., is responding to a growing demand for convenient,
rapid, personalized, and high-quality lab testing —anytime and
anywhere. The company specializes in bio sample collection,
processing, and reporting to deliver actionable information to the
end user by utilizing collection devices, point-of-care (POC)
technologies, Lab Developed Test (LDT) assays, a data-driven
analysis engine and telemedicine. The initial Test2Treat.me
platform will be available at-home, in pharmacies and physician’s
offices and offer diagnostic testing for SARs-CoV-2, respiratory
syncytial virus (RSV) and influenza A/B, urinary tract infections
(UTIs) and sexually transmitted infections (STIs).
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company's intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company's ongoing and planned product and business development;
the Company’s ability to finance and execute on its strategic
M&A initiatives; the Company’s ability obtain the necessary
funding and partner to commence clinical trials; the Company's
intellectual property position; the Company's ability to develop
commercial functions; expectations regarding product launch and
revenue; the Company's results of operations, cash needs, spending,
financial condition, liquidity, prospects, growth and strategies;
the Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled "Risk Factors" in the Company's most recent Annual
Report on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company's other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231005425695/en/
IR@aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024